Posted by Michael Wonder on 01 Jul 2021
Additional treatment option – Tremfya – now available on the PBS for Australians with active psoriatic arthritis
1 July 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Tremfya (guselkumab) is now available on the Pharmaceutical Benefits Scheme for adults with active psoriatic arthritis who have had an inadequate response to, or are intolerant to, prior disease- modifying anti-rheumatic drug therapy.
Tremfya was included in the Australian Register of Therapeutic Goods for use in adults with active psoriatic arthritis in January 2021.
